Vergent is developing tumor-targeted agents that enhance surgeons’ ability to visualize tumors intraoperatively, making cancer surgery more successful for them and their patients.
Vergent Bioscience’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all solid tumor tissue is removed.
Vergent Bioscience's policy covers personal data collected through the site, its use and protection, and user choices. It excludes offline data except as stated for California residents and notes links to third-party websites, content, and services.
Vergent Biosciences owns, controls, and maintains the website for informational and educational purposes. Accessing its materials is subject to terms of use and acknowledges its intellectual property rights.
